Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging

Overview

In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer. The pathologies of the patients who were decided to undergo radical prostatectomy as a treatment will also be compared with the staging tests.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 5, 2023

Interventions

  • Diagnostic Test: Multiparametric Prostate MRI
    • Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer

Clinical Trial Outcome Measures

Primary Measures

  • Lesion location
    • Time Frame: Between prostate biopsy and curative treatment decision , usually 2 month
    • Both MRI and PET results will be compared. Lesion location will be defined as “left”, “right”, “apical”, “basal”, “midline”.
  • Lesion Size
    • Time Frame: Between prostate biopsy and curative treatment decision , usually 2 month
    • Both MRI and PET results will be compared, Lesion size will be stated in milimeters.
  • Lymph node involvement
    • Time Frame: Between prostate biopsy and curative treatment decision , usually 2 month
    • Both MRI and PET results will be compared. Involvement will be stated as “exist”, “non-exist”.
  • Extraprostatic involvement
    • Time Frame: Between prostate biopsy and curative treatment decision , usually 2 month
    • Both MRI and PET results will be compared. Involvement will be stated as “exist” , “non-exist”.
  • Local and distant metastasis
    • Time Frame: Between prostate biopsy and curative treatment decision , usually 2 month
    • Both MRI and PET results will be compared. Metastasis will be stated as “exist” , “non-exist”.

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosed with prostate cancer – Gleason score 7 or above / 6 with high risk – No other treatment Exclusion Criteria:

  • treated with radiotherapy – treated with ADT

Gender Eligibility: Male

Because of prostate cancer study

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gulhane Training and Research Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Can Sicimli, Principal Investigator – Gulhane Training and Research Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.